What is it?
Lysine–proline–valine (KPV). Synthetic tripeptide; evaluated as free base and acetate
Peptide Library · checked July 25, 2026
KPV
KPV has anti-inflammatory findings in cells and mice. FDA says it found no clinical studies or human exposure data by any route. PCAC's July 23 recommendations were narrowly favorable—8–6–1 for each form—but they are not FDA approval or final list placement.
TL;DR
The lowdown
Four answers first. The source record follows.
What do humans show?
FDA identified no clinical studies or human exposure data through any route
Where does FDA stand?
PCAC recommended inclusion for KPV free base and acetate, 8 yes–6 no–1 abstain on each; final FDA determination pending
What is known—and not?
An absence of human adverse-event reports cannot establish safety when FDA found no human exposure data and reporting for compounded products is incomplete. FDA also raises concerns about peptide-related impurities, aggregation, immunogenicity, and the lack of information needed to characterize injectable products.
U.S. status · July 25, 2026
Approval, compounding, product, sport.
- FDA approval
- Not an FDA-approved drug component; PCAC recommended 503A Bulks List inclusion for free base and acetate; final FDA determination pending
- U.S. federal record
- Not an FDA-approved drug component; PCAC recommended 503A Bulks List inclusion for free base and acetate; final FDA determination pending
- Product identity
- No separate finished-product identity conclusion is recorded in this reviewed source.
- Sport
- No WADA status recorded in the reviewed source.
This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.
01
What it is
KPV is a three-amino-acid peptide associated with the carboxyl-terminal sequence of alpha-melanocyte-stimulating hormone. Online discussions often turn mechanistic and animal findings into broad claims about inflammatory conditions. The public evidence does not support that leap.
02
What humans actually show
- Cells and mice: A 2008 study tested KPV in cultured human intestinal and immune-cell lines and two mouse models of colitis. It reported changes in inflammatory signaling and reduced inflammation in the mouse models. This was not a human treatment trial.
- Human treatment evidence: FDA's 2026 review says it did not identify data such as clinical studies on KPV use in humans. It also says no clinical studies or human exposure data were identified through any route.
- Pharmacokinetics and safety: FDA says it found no human pharmacokinetic or pharmacodynamic studies and no clinical safety studies or human exposure data.
The accurate conclusion is “preclinical signal, human effect unknown”—not “proven anti-inflammatory peptide.”
03
FDA and U.S. status
FDA evaluated KPV free base and KPV acetate for proposed wound-healing uses. Staff concluded the criteria weigh against placing either substance on the 503A Bulks List. The briefing says neither is a component of an FDA-approved drug and identifies characterization, effectiveness, and safety gaps.
On July 23, 2026, PCAC voted 8 yes, 6 no, 1 abstain on the free base and 8 yes, 6 no, 1 abstain on the acetate, recommending inclusion for both forms. The committee's recommendation is advisory: it does not approve KPV, authorize a specific product, or itself place either form on the 503A Bulks List. FDA's final determination remains pending.
04
Risks and warning limits
An absence of human adverse-event reports cannot establish safety when FDA found no human exposure data and reporting for compounded products is incomplete. FDA also raises concerns about peptide-related impurities, aggregation, immunogenicity, and the lack of information needed to characterize injectable products.
PepCurrent does not provide dosing, sourcing, or product-selection advice.
05
What would change this answer
- FDA's written meeting record and final determination after the advisory recommendation
- Any registered, controlled human trial that administers a clearly identified KPV substance
- Better identity, impurity, and route-specific safety data
06
Sources and records
- FDA staff briefing — KPV-related bulk drug substances (2026)
- Dalmasso et al., 2008 — cell and mouse colitis study
- FDA meeting page — July 23–24, 2026 PCAC
- FDA voting questions — exact free-base and acetate questions (PDF)
- FDA-linked Day 1 archived broadcast — KPV votes
Educational journalism only; not medical or legal advice. We do not link vendors or publish protocols.
What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-18Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.